← Retour au Screener

Sector: Santé
Open in Terminal → XNCRLive chart · Key metrics · News · Smart money

Xencor

XNCR Small Cap

Healthcare · Biotechnology

Mis à jour: Aug 2, 2026, 22:14 UTC

17,55 €
-5.96% aujourd'hui
52W: 6,01 € – 18,89 €
52W Low: 6,01 € Position: 89.6% 52W High: 18,89 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
15.39x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,3 Md €
Capitalisation boursière
Croissance du CA
-86.2%
Croissance du CA sur un an
Marge bénéficiaire
-177.1%
Marge nette
ROE
-29.84%
Rentabilité des capitaux propres
Beta
0.86
Sensibilité au marché
Positions vendeuses
20.77%
% du flottant vendu à découvert
Volume moyen
931,185
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
12 analysts
Avg. Price Target
24,60 €
+40.19% upside
Target Range
12,16 € – 37,34 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 260 Exchange: NGM

Xencor en bref

Xencor (XNCR) is currently trading at 17,55 € with a market capitalization of 1,3 Md €. The 52-week range spans from 6,01 € to 18,89 €; the current price is 7.1% below the yearly high. Year-over-year revenue growth stands at -86.2%.

💰 Dividende

Xencor currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

12 analystes évaluent Xencor (XNCR) au consensus : Achat Fort. L'objectif de cours moyen est de 24,60 €, soit un potentiel de +40.19% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 12,16 € à 37,34 €.

Xencor : la thèse d'investissement en détail

Xencor (XNCR) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 40.19% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -86.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 20.77% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 40.19% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 33.97)
Points faibles
  • CA en contraction (-86.2% sur un an)
  • Actuellement non rentable
  • Positions vendeuses élevées (20.77%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
12,82 €
+36.92% vs. cours
MM 200 jours
11,99 €
+46.34% vs. cours
Sous le plus haut 52s
−7.1%
18,89 €
Au-dessus du plus bas 52s
+192.1%
6,01 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.86 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
20.77% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
33.97 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (20.77%).

Trading Data

50-Day MA: 12,82 €
200-Day MA: 11,99 €
Volume: 1,318,724
Avg. Volume: 931,185
Short Ratio: 10.98
P/B Ratio: 2.9x
Debt/Equity: 33.97x
Free Cash Flow: -66 758 188 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Xencor?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut